Preanalytical stability of plasma biomarkers for Alzheimer's disease pathology.
| Title: | Preanalytical stability of plasma biomarkers for Alzheimer's disease pathology. |
|---|---|
| Authors: | Sunde AL; Centre for Age-Related Medicine (SESAM) Stavanger University Hospital Stavanger Norway.; Department of Clinical Medicine University of Bergen Bergen Norway.; Alsnes IV; Department of Public Health University of Stavanger Stavanger Norway.; Aarsland D; Centre for Age-Related Medicine (SESAM) Stavanger University Hospital Stavanger Norway.; Department of Old Age Psychiatry Institute of Psychiatry Psychology and Neuroscience King's College London UK.; Ashton NJ; Centre for Age-Related Medicine (SESAM) Stavanger University Hospital Stavanger Norway.; Department of Psychiatry and Neurochemistry Institute of Neuroscience & Physiology the Sahlgrenska Academy at the University of Gothenburg Mölndal Sweden.; King's College London Institute of Psychiatry Psychology and Neuroscience Maurice Wohl Institute Clinical Neuroscience Institute London London UK.; NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South London & Maudsley NHS Foundation London UK.; Tovar-Rios DA; Centre for Age-Related Medicine (SESAM) Stavanger University Hospital Stavanger Norway.; Faculty of Health Sciences University of Stavanger Stavanger Norway.; Grupo INFERIR Facultad de Ingeniería Universidad del Valle Santiago de Cali Valle del Cauca Colombia.; De Santis G; Department of Psychiatry and Neurochemistry Institute of Neuroscience & Physiology the Sahlgrenska Academy at the University of Gothenburg Mölndal Sweden.; Blennow K; Department of Psychiatry and Neurochemistry Institute of Neuroscience & Physiology the Sahlgrenska Academy at the University of Gothenburg Mölndal Sweden.; Zetterberg H; Department of Psychiatry and Neurochemistry Institute of Neuroscience & Physiology the Sahlgrenska Academy at the University of Gothenburg Mölndal Sweden.; Clinical Neurochemistry Laboratory Sahlgrenska University Hospital Mölndal Sweden.; Department of Neurodegenerative Disease UCL Institute of Neurology London UK.; UK Dementia Research Institute at UCL London UK.; Hong Kong Center for Neurodegenerative Diseases Hong Kong China.; Kjosavik SR; The General Practice and Care Coordination Research Group Stavanger University Hospital Stavanger Norway. |
| Source: | Alzheimer's & dementia (Amsterdam, Netherlands) [Alzheimers Dement (Amst)] 2023 May 12; Vol. 15 (2), pp. e12439. Date of Electronic Publication: 2023 May 12 (Print Publication: 2023). |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Wiley on behalf of the Alzheimer's Association Country of Publication: United States NLM ID: 101654604 Publication Model: eCollection Cited Medium: Print ISSN: 2352-8729 (Print) Linking ISSN: 23528729 NLM ISO Abbreviation: Alzheimers Dement (Amst) Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Publication: 2020- : [Hoboken, NJ] : Wiley on behalf of the Alzheimer's Association; Original Publication: [Amsterdam] : Elsevier B.V., [2015]- |
| Abstract: | Introduction: Plasma tests have demonstrated high diagnostic accuracy for identifying Alzheimer's disease pathology. To facilitate the transition to clinical utility, we assessed whether plasma storage duration and temperature affect the biomarker concentrations.; Methods: Plasma samples from 13 participants were stored at +4°C and +18°C. Concentrations of six biomarkers were measured after 2, 4, 6, 8, 10, and 24 h by single molecule array assays.; Results: Phosphorylated tau 181 (p-tau181), phosphorylated tau 231 (p-tau231), neurofilament light (NfL), and glial fibrillary acidic protein (GFAP) concentrations were unchanged both when stored at +4°C and +18°C. Amyloid-β 40 (Aβ40) and amyloid-β 42 (Aβ42) concentrations were stable for 24 h at +4°C but declined when stored at +18°C for longer than 6 h. This decline did not affect the Aβ42/Aβ40 ratio.; Discussion: Plasma samples can be stored for 24 h at +4°C or +18°C and result in valid assay results for p-tau181, p-tau231, Aβ42/Aβ40 ratio, GFAP, and NfL.; Highlights: Plasma samples were stored for 24 h at +4°C and +18°C, mimicking clinical practice.Concentrations for Alzheimer's disease biomarkers were measured at six time-points.p-tau181, p-tau231, NfL, and GFAP concentrations were unchanged during the experiment.Storage at +18°C affected Aβ40 and Aβ42 concentrations while storage at +4°C did not. The Aβ42/Aβ40 ratio was unaffected.These plasma tests seem suitable for use in general practice.; (© 2023 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.) |
| Competing Interests: | A.L. Sunde, I.V. Alsnes, N.J. Ashton, D.A. Tovar‐Rios, G. De Santis, and S.R. Kjosavik report no conflict of interest. K. Blennow has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers; and is a co‐founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. H. Zetterberg has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Passage Bio, Pinteon Therapeutics, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co‐founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). D. Aarsland has received a research grant and honoraria from Roche Diagnostics (outside submitted work). Author disclosures are available in the supporting information. |
| References: | Acta Neuropathol. 2021 May;141(5):709-724. (PMID: 33585983); Gerontologist. 2019 Nov 16;59(6):e697-e708. (PMID: 29939234); Brain. 2021 Dec 16;144(11):3505-3516. (PMID: 34259835); Alzheimers Dement (Amst). 2023 May 12;15(2):e12439. (PMID: 37192842); Lancet. 2021 Apr 24;397(10284):1577-1590. (PMID: 33667416); Alzheimers Res Ther. 2022 Mar 29;14(1):46. (PMID: 35351181); Scand J Prim Health Care. 2020 Jun;38(2):107-116. (PMID: 32362213); Medicina (Kaunas). 2022 Jul 07;58(7):. (PMID: 35888625); Neurosci Biobehav Rev. 2021 Sep;128:479-486. (PMID: 34245759); Alzheimers Dement. 2022 Aug;18(8):1484-1497. (PMID: 34845818); J Neurol Neurosurg Psychiatry. 2021 Nov;92(11):1231-1241. (PMID: 34510001); Alzheimers Dement (Amst). 2022 May 15;14(1):e12285. (PMID: 35603139); Nat Med. 2021 Jun;27(6):1034-1042. (PMID: 34031605); Nat Commun. 2021 Jun 7;12(1):3400. (PMID: 34099648); Nat Med. 2020 Mar;26(3):379-386. (PMID: 32123385); Alzheimers Dement (Amst). 2019 Apr 02;11:291-300. (PMID: 30984815); Alzheimers Dement (Amst). 2018 Jul 02;10:448-451. (PMID: 30211292); Alzheimers Dement (Amst). 2021 Jun 02;13(1):e12168. (PMID: 34124336); Lancet Neurol. 2020 May;19(5):422-433. (PMID: 32333900); JAMA Neurol. 2019 Sep 01;76(9):1060-1069. (PMID: 31233127); Front Aging Neurosci. 2022 Jul 25;14:942629. (PMID: 35959295) |
| Contributed Indexing: | Keywords: Alzheimer disease; amyloid beta; biomarker; glial fibrillary acidic protein; neurofilament protein light; phosphorylated tau; plasma; pre‐analytics |
| Entry Date(s): | Date Created: 20230516 Latest Revision: 20240918 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC10182363 |
| DOI: | 10.1002/dad2.12439 |
| PMID: | 37192842 |
| Database: | MEDLINE |
Journal Article